Scientists from France have created a revolutionary innovation that could change the “rules of the game” in the treatment of type 2 diabetes and weight loss.
The new development concerns a modified version of the active substance semaglutide, which is already used in the well-known drugs Ozempic and Vegovi. In contrast to the current practice, which requires weekly administration of the drug, The new formulation is an injectable hydrogel that is administered only once a month.
This innovation, called “Gelzepmic» (or officially AdoGel Sema)developed by the French biotechnology company Adocia with the aim of improving the daily lives of patientsAdocia is known for its efforts to create innovative formulations of existing drugs, particularly in the area of insulin, which is already undergoing large-scale clinical trials.
What is Semaglutide and How Does it Help?
Semaglutide, a drug that has already revolutionized the treatment of type 2 diabetes, is also helps to reduce weight significantlyClinical trials have shown that patients taking this drug lose an average of 15% of their body weightwhich is much higher than with diet or exercise alone. Despite side effects such as nausea and gastrointestinal problems, The effectiveness of semaglutide is undeniable.
There is one big problem, however: only 40% of patients continue to take the drug after a year. The need for weekly dosing, combined with side effects, causes many patients to stop treatment.
Revolutionary hydrogel
A new formulation of semaglutide, available as an injectable hydrogel, offers a solution to this problem. This The gel releases the medicine gradually over the course of a month.ensuring that patients will require fewer doses and therefore less frequent visits to the doctor.
The technology behind Gelzepmic includes two biodegradable polymers that help release the drug gradually. Tests on rats showed excellent results, as the new version of the drug was just as effective and well tolerated, with no signs of inflammation or toxicity.
Adocia scientists plan to continue testing in pigs, whose skin and endocrine systems are more similar to humans. If all goes well, clinical trials in humans will begin in the next few years. In the meantime, the company is also working on a new tablet formulation of semaglutide, early indications are that it is absorbed more efficiently than existing ones. Rybelsus tablets.
The first results of this innovative study will be presented at the annual conference of the European Association for the Study of Diabetes (EASD), which will be held in Madrid from 9 to 13 September. With this new form of semaglutide, scientists appear to be taking a step forward to make life easier for millions of patients worldwide by offering a simpler and more effective way to manage diabetes and lose weight.
More Stories
Severe Back Pain: When to See a Doctor, What You Need to Know
Expert Opinion: Very Popular Diet Raises Diabetes Risk
Artificial intelligence system capable of diagnosing over 1000 diseases at an early stage